CTLA-4 blockade causes a broad enhancement of immune responses and the systemic delivery of anti-CTLA-4 blocking antibodies is currently FDA approved for the treatment of melanoma and renal cell carcinoma. This evidence concerns the gene CTLA4 and hereditary clear cell renal cell carcinoma.